All News
Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis
A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.
Read Article
Predicting Spondylitis in At-Risk Relatives
The risk of developing axial spondyloarthritis (axSpA) if you’re a first-degree relative (FDRs) of an ankylosing spondylitis (AS) patient has been deflined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of acute anterior uveitis (AAU).
Read Article
#ClinicalPearl Thickened R Achilles’ tendon, dry flakey skin, dystrophic toe nails = .....? https://t.co/ERVYkeJuuA
Janet Pope Janetbirdope ( View Tweet)
Join Dr. Pamela Weiss, this weekend at RheumNow Live where she will present and discuss Juvenile Spondyloarthritis.
Full the full agenda, and to register, head to https://t.co/2dcFVgu8z6 https://t.co/WLDVXy7bYT
Links:
Dr. John Cush RheumNow ( View Tweet)
UK study of 4·16 million adults/children, shows incidence of Alopecia Areata (AA) to be 0·26/ 1000 person-yrs. AA point prevalence 0·58% in 2018, peaked ages 25–29 years, more likely in nonwhites, those w/ social deprivation & urban living https://t.co/RzuBLt5pmS https://t.co/mmwS9nRfbN
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live starts this Saturday! Are you registered yet?
https://t.co/x3JJP8uZR4
What session are you most looking forward to? https://t.co/rP54RLUYw2
Links:
Dr. John Cush RheumNow ( View Tweet)
COVID-19 mRNA Vaccine Safety #s - From ~300 million doses, there were 340,522 VAERS reported side effects, 92% mild, 6·6% serious (non-death)& 1·3% deaths(none from Anaphylaxis-0.025%). From 7.9 million V-safe participants, 1/2 had some AE. https://t.co/LV3aiOBOah https://t.co/mbYkZeywEo
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 338 psoriatic pts assessed carotid total plaque area (TPA) and cardiac troponin I (cTnI) & NT-proBNP. TPA was associated with troponin 1 (β coefficient 0.52) and NT-proBNP (β coefficient 0.24); both p<0.001. https://t.co/NXUBByAD37 https://t.co/ZQMFiqTzDF
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study of 338 pregnancies in IMID pts (~1/2 w/ IBD); 23% w/ biologic exposure had increase in post-partum flares (OR 3.44) & less being breastfeed (OR 0.44). Maternal and neonatal pregnancy outcomes were similar https://t.co/8pu2p8tK0s https://t.co/bVQx9La5j3
Links:
Dr. John Cush RheumNow ( View Tweet)
Korean study (TB endemic area) shows the risk of mTB & nontuberculous mycobact infx (NTM) are equal and nearly doubled in RA pts on TNFi. Among 4356 RA (1089 on TNFi) NTM & TB rates were 328- and 341/100K PY (US rate is 6/100K PY) https://t.co/QwzTYt3wX4 https://t.co/GLWreoQ6ih
Dr. John Cush RheumNow ( View Tweet)
ICYMI: CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/jM8UKwBp7u https://t.co/fOc8Ay8KU3
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is Coming to Town!
Have you signed up for RheumNow Live yet? We still have space available.
https://t.co/FBCQRu32gO
https://t.co/KoGR8An6af https://t.co/qtwPbMzqSO
Dr. John Cush RheumNow ( View Tweet)
ICYMI: anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/6MQ3CMU7YG https://t.co/okl2e1Q6Hs
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Kawasaki Disease Guideline from ACR and Vasculitis Foundation
https://t.co/ixKL6juqkM https://t.co/Nw4yi0OZPy
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA.
- Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality
- Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks
- Steroid sparing w/ MTX, AZA or TNFi https://t.co/Ue4V1uAhRF https://t.co/5ap3bPzoNk
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Undifferentiated Arthritis Does Not Follow an RA Course
UA is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach.
https://t.co/l0U4IVAXMG https://t.co/8YPM8DgX8H
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/tg5eETiMO4 https://t.co/bC45AAnP3h
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is Coming to Town!
Have you signed up for RheumNow Live yet? We still have space available. It kicks off one week from today!
https://t.co/mMlAC3OXTJ
https://t.co/DY32PxQnRm https://t.co/kcIQ2GdObr
Dr. John Cush RheumNow ( View Tweet)
The Differential on Tenosynovitis
70 yr old man with tenosynovitis - imagine the possibilities
QD Clinic is sponsored by https://t.co/4UQlqwujiR
(March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/HraAZHIKA9 https://t.co/nzG6tlXuJU
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
https://t.co/XYK02MRMp6 https://t.co/LgToS5NCaa
Links:
Dr. John Cush RheumNow ( View Tweet)